Filing Flows › Pelthos Therapeutics (PTHS) › Q3 2025
Pelthos Therapeutics (PTHS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Pelthos Therapeutics (PTHS) reported revenue of $7.4M for the third quarter 2025 (Q3 2025). Operating margin was -207.4%, net loss $16.2M (219.3% of revenue).
Pelthos Therapeutics, Q3 2025: revenue $7.4M, operating margin -207.4%, net loss $16.2M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.4M | — | — |
| Operating profit | −$15.4M | — | — |
| Net earnings | −$16.2M | — | — |
| Operating cash flow | −$15.3M | — | — |
What changed
Revenue was $7.4M in Q3 2025.
Operating costs exceeded revenue by $15.4M, an operating margin of -207.4%. The quarter ended with a net loss of $16.2M.
Operating cash flow was −$15.3M. Non-cash charges added back $2.8M of share-based compensation. Working capital and other items used $1.8M.
Questions
What was Pelthos Therapeutics' revenue in the third quarter 2025?
Pelthos Therapeutics (PTHS) reported revenue of $7.4M for the third quarter 2025 (Q3 2025).
Was Pelthos Therapeutics profitable in the third quarter 2025?
Operating loss was $15.4M (-207.4% of revenue) and net loss $16.2M.